DOI: 10.1097/qad.0000000000004607 ISSN: 0269-9370
Comorbidity burden and outcomes with long-acting cabotegravir plus rilpivirine in the RELATIVITY cohort
Jesús Troya, Carmen Busca, Mariano Matarranz, María José Galindo, María Fernández-Regueras, María Belén Sánchez-López, Dácil García-Rosado, Miguel Torralba, Alberto Díaz De Santiago, Francisco Fanjul, Adrián Rodríguez, Alfonso Cabello-Úbeda, María José Crusells-Canales, María del Carmen Navarro, Ignacio De los Santos, Carmen Hidalgo, Luis Enrique Morano-Amado, David Vinuesa-García, Carlos De Andrés David, Enrique Bernal, Ruth Caballero, Alberto Romero, Juan Tiraboschi, Alejandra Gimeno-García, Eva María Ferreira, Juan Emilio Losa-García, Luis Buzón-MartínIn RELATIVITY, among 3118 virologically suppressed people with HIV switching to long-acting cabotegravir plus rilpivirine, 40.0% had at least one comorbidity and 16.8% had multimorbidity. Higher comorbidity burden identified older, clinically complex participants with longer ART exposure, lower CD4 nadir, and more prior AIDS. Virological failure (0.6–0.8%), definitive discontinuation (4.3–6.3%), and complete injection coverage, defined as proportion of days covered (PDC) of 100% (83.4–87.2%) were similar across strata, suggesting that comorbidity burden alone should not preclude individualized use in routine care.